Head and neck cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 70
• PD-L1 42
• TP53 7
• EGFR 33
• PI3K 6
• STAT3 1
• BRAF 0
• AKT 2
• mTOR 0
• HER2 6
• RET 0
• MAPK 0
• ERK 0
• STING 0
• PTEN 1
• TERT 0
• CTNNB1 0
• JAK 1
• CTLA-4 4
• NRF2 0
• MYC 0
• VEGF 4
• YAP 1
• HIF-1 0
• MET 3
• AMPK 0
• CLDN18 0
• IL-6 2
• JNK 0
• PARP 1
• FGFR 1
• GPX4 0
• B7-H3 5
• CD47 1
• COX-2 0
• LAG-3 2
• TROP2 5
• EZH2 0
• MEK 0
• METTL3 0
• PIK3CA 4
• CDK4/6 2
• NLRP3 0
• ATM 0
• PKM2 0
• TNF 0
• FAK 0
• MMP-9 0
• PPAR 0
• PSMA 1
• TLR4 0
• BCL-2 0
• HSP90 0
• KRAS 0
• NOTCH1 0
• NTRK 1
• ALK 0
• CD40 1
• CDKN2A 2
• CXCR4 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIDCR · F31

  Investigating the impact of radiation therapy on oral squamous cell carcinoma microenvironment via non-classical class I major histocompatibility complex HLA-E

  University of California at Davis· Davis, United States· US$43,748 awarded in fiscal year 2026· until Aug 2029

• NIH NIDCR · F32

  Transposon derived neo-antigens in NSD1 mutant Head and Neck Cancers

  Columbia University Health Sciences· New York, United States· US$77,580 awarded in fiscal year 2026· until Sept 2028

• NIH NIAID · R56

  Functional dissection of a novel E2 complex critical for the HPV16 life cycle

  Virginia Commonwealth University· Richmond, United States· US$768,308 awarded in fiscal year 2026· until Aug 2027

• NIH NIDCR · R01

  Restoring responses to immunotherapy in metastatic lymph nodes in HNSCC

  University of California, San Francisco· San Francisco, United States· US$684,832 awarded in fiscal year 2026· until Jul 2031

• NIH NIDCR · R01

  Advancing FTIR-based Multimodal Imaging with AI for Risk Stratification of Oral Precancer

  University of Missouri Kansas City· Kansas City, United States· US$527,533 awarded in fiscal year 2026· until Jun 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetic Profiling and Telomere-Orchestrated Mechanisms in HPV+ Oropharyngeal Cancer (EPiTOME-M)

  Royal College of Surgeons in Ireland· Dublin 2, Ireland· EU contribution €268,569· until Nov 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Endoscopic tissue time machine (EPIC)

  King's College London· London, United Kingdom· EU contribution €2,273,033· until May 2031

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  From Whisper to Voice: Real-Time on-Device Assistive AI Technology for Human Connection (Whispp)

  Whispp Bv· Leiden, Netherlands· EU contribution €2,498,319· until May 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  INHIBITING RESISTANCE TO IMMUNOTHERAPY IN HEAD&NECK CANCER BY TARGETING NETRIN-1 (NeckNET)

  Netris Pharma Sas· Lyon, France· EU contribution €7,248,398· until May 2030· 4 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  Early clinical development of first-in-class EGL-001 targeting Tregs in head and neck squamous cell carcinoma, supported by AI-based pathomics (NEOTREG)

  Egle Therapeutics· Suresnes, France· EU contribution €7,999,120· until Nov 2028· 4 countries

10 of 564 running projects, newest first. Listed amounts together: US$326.5m + €36.6m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 84
• Organoids 23
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 13
• Gene Expression Profiling 244
• Sequence Analysis, RNA 26
• Whole Genome Sequencing 7
• Exome Sequencing 22
• Proteomics 65
• Metabolomics 43
• Mass Spectrometry 14
• Flow Cytometry 56
• Immunohistochemistry 333
• Liquid Biopsy 34
• Circulating Tumor DNA 57
• Xenograft Model Antitumor Assays 308
• Positron-Emission Tomography 83
• Magnetic Resonance Imaging 276
• Machine Learning 232
• Deep Learning 187
• Cohort Studies 296
• Genome-Wide Association Study 55

• Combining Intravital Microscopy and Transcriptomic Analysis to Study Head and Neck Squamous Cell Carcinoma.

  Methods Mol Biol, Jan 2027

• Global burden of chewing-tobacco-attributable oral cancer and genomic-transcriptomic profiling of cigarette-smoking-associated oral cavity tumors.

  Funct Integr Genomics, Nov 2026

• Integrated Transcriptomic Analysis Suggests THBS2 as a Candidate Fibroblast-Associated Marker in Oral Lichen Planus and Oral Squamous Cell Carcinoma.

  J Vis Exp, Nov 2026

• Explainable computational framework for subtype classification and biomarker identification in head and neck squamous cell carcinoma using machine learning.

  PLoS One, Nov 2026

• Gene Expression Profiling and Clinical Validation Reveal CEBPB for Early Diagnosis of Esophageal Squamous Cell Carcinoma.

  Cancer Rep (Hoboken), Nov 2026

• MGP_HNSC32: A H&E Morphology-Derived 32-Gene Prognostic Signature in Head and Neck Squamous Cell Carcinoma.

  Cancer Med, Nov 2026

• Decoder-FFPE-seq enables sensitive, genome-wide spatial transcriptomics of archival tissues at single-cell resolution.

  Sci Adv, Oct 2026

• Identification of prognostic biomarkers for nasopharyngeal carcinoma through microRNA‑mRNA network analysis combined with screening of immune‑related genes.

  PLoS One, Oct 2026

• Early vs late fusion of qMIDS with machine learning based classifiers for oral cancer diagnosis from gene expression data.

  PLoS Comput Biol, Oct 2026

• Multi-omics integration identifies serum FTL as a novel diagnostic biomarker for esophageal squamous cell carcinoma.

  Front Immunol, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.